IL255026A0 - A fasting-mimicking diet and glucose-lowering drugs that protect normal cells and produce cancer-susceptible states in response to rapamycin- and dexamethasone-induced standard and high-glucose conditions - Google Patents

A fasting-mimicking diet and glucose-lowering drugs that protect normal cells and produce cancer-susceptible states in response to rapamycin- and dexamethasone-induced standard and high-glucose conditions

Info

Publication number
IL255026A0
IL255026A0 IL255026A IL25502617A IL255026A0 IL 255026 A0 IL255026 A0 IL 255026A0 IL 255026 A IL255026 A IL 255026A IL 25502617 A IL25502617 A IL 25502617A IL 255026 A0 IL255026 A0 IL 255026A0
Authority
IL
Israel
Prior art keywords
conditions
fmd
rapamycin
dexamethasone
standard
Prior art date
Application number
IL255026A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of IL255026A0 publication Critical patent/IL255026A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL255026A 2015-04-16 2017-10-15 A fasting-mimicking diet and glucose-lowering drugs that protect normal cells and produce cancer-susceptible states in response to rapamycin- and dexamethasone-induced standard and high-glucose conditions IL255026A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (1)

Publication Number Publication Date
IL255026A0 true IL255026A0 (en) 2017-12-31

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255026A IL255026A0 (en) 2015-04-16 2017-10-15 A fasting-mimicking diet and glucose-lowering drugs that protect normal cells and produce cancer-susceptible states in response to rapamycin- and dexamethasone-induced standard and high-glucose conditions

Country Status (14)

Country Link
US (2) US20160303056A1 (cg-RX-API-DMAC10.html)
EP (2) EP4299061A3 (cg-RX-API-DMAC10.html)
JP (2) JP2018511625A (cg-RX-API-DMAC10.html)
KR (1) KR20180002677A (cg-RX-API-DMAC10.html)
CN (1) CN107613979A (cg-RX-API-DMAC10.html)
AU (1) AU2016248443B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017022244A2 (cg-RX-API-DMAC10.html)
CA (2) CA3108664A1 (cg-RX-API-DMAC10.html)
HK (1) HK1249858A1 (cg-RX-API-DMAC10.html)
IL (1) IL255026A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017013133A (cg-RX-API-DMAC10.html)
RU (1) RU2734774C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016168802A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201707710B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291693A4 (en) * 2015-05-06 2019-04-03 University of Southern California FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER
JP2019505592A (ja) 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
KR20180136551A (ko) 2016-05-11 2018-12-24 유니버시티 오브 써던 캘리포니아 위장 자가면역/염증 질환을 위한 면역조절 치료로서의 단식 모방 식이(fmd)
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
US12628858B2 (en) 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
EP3963599B1 (en) 2019-04-30 2026-06-03 University of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP2023529504A (ja) * 2020-06-14 2023-07-10 エル-ニュートラ・インコーポレイテッド ファスティング状態を維持及び延長する断続的なファスティングバー/ドリンク
WO2022008943A1 (ru) * 2020-07-10 2022-01-13 Елена Анатольевна МАРТЫНОВА Способ проведения курса голодания для тяжелобольных пациентов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
CA2900782C (en) * 2013-02-12 2022-09-27 University Of Southern California Methods and diets to protect against chemotoxicity and age related illnesses
RU2727960C2 (ru) * 2013-07-01 2020-07-28 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用

Also Published As

Publication number Publication date
RU2017136423A3 (cg-RX-API-DMAC10.html) 2019-09-04
CN107613979A (zh) 2018-01-19
EP4299061A2 (en) 2024-01-03
US20210137856A1 (en) 2021-05-13
RU2734774C2 (ru) 2020-10-23
EP4299061A3 (en) 2024-02-28
AU2016248443B2 (en) 2021-03-18
JP2021008491A (ja) 2021-01-28
ZA201707710B (en) 2019-04-24
EP3283073A2 (en) 2018-02-21
BR112017022244A2 (pt) 2018-07-10
JP2018511625A (ja) 2018-04-26
HK1249858A1 (zh) 2018-11-16
KR20180002677A (ko) 2018-01-08
CA2982875A1 (en) 2016-10-20
AU2016248443A1 (en) 2017-11-02
EP3283073A4 (en) 2019-02-13
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
CA2982875C (en) 2021-10-19
RU2017136423A (ru) 2019-05-16
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07

Similar Documents

Publication Publication Date Title
ZA201707710B (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
SG11201709321RA (en) Preparation method for solar cell piece unit and solar cell module
SMT201900681T1 (it) Protezione transitoria di cellule normali durante la chemioterapia
EP3238070A4 (en) Memory protection with non-readable pages
EP2923248A4 (en) Reversible folio for tablet computer with reversible connection for keyboard and reading configuration
EP3019936A4 (en) Fast multi-touch post processing
EP3084830A4 (en) Liner for phase change memory (pcm) array and associated techniques and configurations
GB2521562B (en) Anti-tumor T cell immunity induced by high dose radiation
EP3069171A4 (en) Seismic data processing
EP3259868A4 (en) Protecting sensitive data security
EP3066496B8 (en) Device and method for detecting neutrons and gamma rays
EP3088951A4 (en) Array substrate, preparation method thereof, motherboard comprising array substrate and display apparatus
EP3135678A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3298918A4 (en) Improvements to skull protection cell
EP3198466A4 (en) Multicore memory data recorder for kernel module
EP2989491A4 (en) CORE RADIATION DETECTOR CALIBRATION IN A BOREOILL
EP3260456A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3241116A4 (en) Memory access protection using processor transactional memory support
EP3140673A4 (en) Gamma detector protection for downhole operations
GB201802711D0 (en) Design structure for reducing pre-charge voltage for static random-access memory arrays
EP3271828A4 (en) Cache and data organization for memory protection
EP3287452A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3031449A4 (en) Entecavir microspheres and pharmaceutical composition for parenteral administration containing same
ZA201505391B (en) Framed implementation for payment widgets
EP3044811A4 (en) Imaging cell array integrated circuit